Michael Biermer

1.6k total citations
40 papers, 902 citations indexed

About

Michael Biermer is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Michael Biermer has authored 40 papers receiving a total of 902 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Epidemiology, 28 papers in Hepatology and 4 papers in Infectious Diseases. Recurrent topics in Michael Biermer's work include Hepatitis B Virus Studies (29 papers), Hepatitis C virus research (27 papers) and Liver Disease Diagnosis and Treatment (17 papers). Michael Biermer is often cited by papers focused on Hepatitis B Virus Studies (29 papers), Hepatitis C virus research (27 papers) and Liver Disease Diagnosis and Treatment (17 papers). Michael Biermer collaborates with scholars based in Germany, United States and Belgium. Michael Biermer's co-authors include Robyn J. Puro, Robert J. Schneider, Uwe Will, Christian Jürgensen, H Seifert, Till Wehrmann, Rainer Gerlach, Thomas Rösch, Alexander Meining and W Schmitt and has published in prestigious journals such as Hepatology, Journal of Virology and Gut.

In The Last Decade

Michael Biermer

35 papers receiving 887 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Biermer Germany 12 454 347 319 270 107 40 902
William Gelson United Kingdom 17 849 1.9× 1.1k 3.2× 304 1.0× 209 0.8× 65 0.6× 42 1.6k
Bidhan Chandra Das Japan 14 174 0.4× 155 0.4× 442 1.4× 169 0.6× 223 2.1× 30 668
Marlene L. Bambrick United States 12 688 1.5× 47 0.1× 619 1.9× 121 0.4× 51 0.5× 18 1.2k
S. Recchia Italy 13 546 1.2× 500 1.4× 283 0.9× 242 0.9× 303 2.8× 36 998
Paresh Kamat United States 6 100 0.2× 118 0.3× 102 0.3× 82 0.3× 80 0.7× 8 388
David L. Smith United States 13 194 0.4× 76 0.2× 86 0.3× 104 0.4× 272 2.5× 19 681
Mohammed Q. Khan Saudi Arabia 16 270 0.6× 229 0.7× 158 0.5× 44 0.2× 55 0.5× 31 507
Edip Akpınar United States 11 77 0.2× 207 0.6× 182 0.6× 96 0.4× 44 0.4× 20 404
M. Chevallier France 16 659 1.5× 639 1.8× 164 0.5× 30 0.1× 94 0.9× 35 984

Countries citing papers authored by Michael Biermer

Since Specialization
Citations

This map shows the geographic impact of Michael Biermer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Biermer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Biermer more than expected).

Fields of papers citing papers by Michael Biermer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Biermer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Biermer. The network helps show where Michael Biermer may publish in the future.

Co-authorship network of co-authors of Michael Biermer

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Biermer. A scholar is included among the top collaborators of Michael Biermer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Biermer. Michael Biermer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gane, Edward, Ewa Janczewska, Tetsuo Takehara, et al.. (2025). Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study. JHEP Reports. 7(10). 101516–101516. 1 indexed citations
2.
3.
Liang, Xieer, Qiaoqiao Chen, Hong Tang, et al.. (2025). Prevalence of Hepatitis D Virus Antibody Positivity in Chinese Patients with Chronic Hepatitis B Virus Infection. Journal of Clinical and Translational Hepatology. 0(0). 0–0.
4.
5.
Agarwal, Kosh, Marı́a Buti, Florian van Bömmel, et al.. (2024). JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. Journal of Hepatology. 81(3). 404–414. 22 indexed citations
6.
Mak, Lung‐Yi, Christine I. Wooddell, Oliver Lenz, et al.. (2024). Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989. Gut. 74(3). 440–450. 17 indexed citations
7.
8.
9.
Verbinnen, Thierry, Willem Talloen, Harry L.A. Janssen, et al.. (2023). Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study. Antiviral Research. 216. 105660–105660. 4 indexed citations
10.
Kakuda, Thomas N., Atef Halabi, G. Klein, et al.. (2023). Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment. The Journal of Clinical Pharmacology. 63(6). 732–741. 3 indexed citations
11.
Wedemeyer, Heiner, Edward Gane, Kosh Agarwal, et al.. (2023). Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study. Journal of Hepatology. 78. S34–S34. 7 indexed citations
12.
13.
Agarwal, Kosh, James Lok, Ivana Carey, et al.. (2022). A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV ‘cure’. Journal of Hepatology. 77(1). 245–248. 40 indexed citations
14.
Takehara, Tetsuo, Kazuaki Chayama, Masayuki Kurosaki, et al.. (2020). JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. Journal of Gastroenterology. 55(6). 640–652. 3 indexed citations
15.
Locarnini, Stephen, Bruce D. Given, Thomas Schluep, et al.. (2019). First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA). Hepatology. 70(6). 7 indexed citations
16.
Eurich, Dennis, Marcus Bahra, Thomas Berg, et al.. (2011). Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.. PubMed. 9(1). 1–6. 23 indexed citations
17.
Biermer, Michael, et al.. (2010). 36 SILIBININ AS A RESCUE TREATMENT FOR HCV-INFECTED PATIENTS SHOWING SUBOPTIMAL VIROLOGIC RESPONSE TO STANDARD COMBINATION THERAPY. Journal of Hepatology. 52. S16–S16. 2 indexed citations
18.
Seifert, H, Michael Biermer, W Schmitt, et al.. (2009). Transluminal endoscopic necrosectomy after acute pancreatitis: a multicentre study with long-term follow-up (the GEPARD Study). Gut. 58(9). 1260–1266. 302 indexed citations
19.
Ahlenstiel, Golo, Hans Dieter Nischalke, Thomas Berg, et al.. (2007). The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. Journal of Hepatology. 47(3). 348–355. 9 indexed citations
20.
Biermer, Michael, Robyn J. Puro, & Robert J. Schneider. (2003). Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity through Activation of NF-κB. Journal of Virology. 77(7). 4033–4042. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William Gelson Breakdown of academic impact, for papers by Bidhan Chandra Das Breakdown of academic impact, for papers by Marlene L. Bambrick Breakdown of academic impact, for papers by S. Recchia Breakdown of academic impact, for papers by Paresh Kamat Breakdown of academic impact, for papers by David L. Smith Breakdown of academic impact, for papers by Mohammed Q. Khan Breakdown of academic impact, for papers by Edip Akpınar Breakdown of academic impact, for papers by M. Chevallier
Rankless by CCL
2026